Norristown, PA, United States of America

Virginia Fitzpatrick

This inventor holds 1 USPTO granted patent. Top assignee: Wyeth. Active years: 2010.


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Virginia Fitzpatrick: Innovator in Drug Activity Monitoring

Introduction

Virginia Fitzpatrick is a notable inventor based in Norristown, PA (US). She has made significant contributions to the field of drug monitoring through her innovative patent. Her work focuses on methods and systems that enhance the understanding of drug activities in vivo.

Latest Patents

Virginia Fitzpatrick holds a patent titled "Methods for monitoring drug activities in vivo." This invention encompasses methods, systems, and equipment that are useful for monitoring the in vivo activities of CCI-779 or other drugs. The invention identifies numerous drug activity genes, which can be modulated by CCI-779 or similar drugs. These genes serve as surrogate markers for detecting or monitoring drug activities in vivo, providing valuable insights into drug efficacy and safety.

Career Highlights

Virginia Fitzpatrick is associated with Wyeth, a prominent pharmaceutical company. Her work at Wyeth has allowed her to contribute to advancements in drug monitoring technologies. With her expertise, she has played a crucial role in developing innovative solutions that enhance patient care and treatment outcomes.

Collaborations

Virginia has collaborated with esteemed colleagues, including Michael E Burczynski and Joseph Boni. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Virginia Fitzpatrick's contributions to drug activity monitoring exemplify her dedication to advancing medical science. Her innovative patent and collaborative efforts highlight her role as a key figure in the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…